Radiology, Vol 199, 743-750, Copyright © 1996 by Radiological Society of North America

ARTICLES

Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro- 2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy

BL Shulkin, RJ Hutchinson, VP Castle, GA Yanik, B Shapiro and JC Sisson
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0029, USA.

PURPOSE: To assess the uptake in neuroblastoma of 2-[fluorine-18] - fluoro-2-deoxy-D-glucose (FDG) versus metaiodobenzylguanidine (MIBG). MATERIALS AND METHODS: Seventeen patients with known or suspected neuroblastoma underwent FDG positron emission tomography (PET) (20 scans) and MIBG scintigraphy. Tumor uptake of FDG was quantified on positive PET scans. RESULTS: Tumor uptake of FDG was detected in 16 of 17 patients (18 of 20 scans). Neuroblastomas and their metastases avidly concentrated FDG prior to chemotherapy or radiation therapy. Uptake after therapy was variable. Uptake of FDG was intense in one patient with neuroblastoma that failed to accumulate MIBG. In 13 of the 20 scans, however, MIBG was rated superior to FDG for delineation of tumor compared with background and normal organs. CONCLUSION: Most neuroblastomas accumulate FDG. The mechanism of MIBG uptake is more intense prior to therapy. Concentration of FDG is not dependent on type 1 catecholamine uptake. FDG PET helps define the distribution of neuroblastomas that fail to concentrate MIBG.

This article has been cited by other articles:

				L Moon and K McHugh Advances in paediatric tumour imaging Arch. Dis. Child., June 1, 2005; 90(6): 608 - 611. [Abstract] [Full Text] [PDF]

				K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]

				B. H. Kushner Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188. [Abstract] [Full Text] [PDF]

				E. G. Roberts and B. L. Shulkin Technical Issues in Performing PET Studies in Pediatric Patients J. Nucl. Med. Technol., March 1, 2004; 32(1): 5 - 9. [Abstract] [Full Text] [PDF]

				C. Franzius, S. Bielack, S. Flege, J. Sciuk, H. Jurgens, and O. Schober Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma J. Nucl. Med., August 1, 2002; 43(8): 1012 - 1017. [Abstract] [Full Text] [PDF]

				B. H. Kushner, H. W.D. Yeung, S. M. Larson, K. Kramer, and N.-K. V. Cheung Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients J. Clin. Oncol., July 15, 2001; 19(14): 3397 - 3405. [Abstract] [Full Text] [PDF]

				B. L. Shulkin, N. W. Thompson, B. Shapiro, I. R. Francis, and J. C. Sisson Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET Radiology, July 1, 1999; 212(1): 35 - 41. [Abstract] [Full Text]